Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Lymphoid 1

Conditions

Melanoma 11Breast Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Carcinoma, Merkel Cell 2Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Carcinoma, Basal Cell 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

pembrolizumab 6Nivolumab 6Ipilimumab 4Radiotherapy 3talimogene laherparepvec 2budigalimab 2avelumab 2atezolizumab 2Everolimus 2Cyclophosphamide 2zimberelimab 1venetoclax 1vatalanib 1tremelimumab 1temsirolimus 1sapanisertib 1rovalpituzumab tesirine 1poly ICLC 1oblimersen 1lorvotuzumab mertansine 1lanreotide 1glucopyranosyl lipid-A 1fludarabine 1durvalumab 1domatinostat 1cixutumumab 1cemiplimab 1aldesleukin 1Vinorelbine 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Merkel Cell × talimogene laherparepvec × Clear all
NCT02819843 2025-01-29

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
19 enrolled 7 charts
Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT03458117 2022-03-18

20139157 T-VEC

University of Zurich

Phase 1 Completed
26 enrolled
DermatologicLymphoid

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡